CO-AMOXICLAV

This brand name is authorized in Nigeria. It is also authorized in Ecuador, Hong Kong SAR China, Ireland, Malta, Poland, South Africa.

Active ingredients

The drug CO-AMOXICLAV contains a combination of these active pharmaceutical ingredients (APIs):

1	Amoxicillin trihydrate UNII 804826J2HU - AMOXICILLIN
	Amoxicillin is a semisynthetic penicillin (beta-lactam antibiotic) that inhibits one or more enzymes (often referred to as penicillin-binding proteins, PBPs) in the biosynthetic pathway of bactericidal peptidoglycan, which is an integral structural component of the bacterial cell wall. Inhibition of peptidoglycan synthesis leads to weakening of the cell wall, which is usually followed by cell lysis and death.
	Read more about Amoxicillin
2	Clavulanic acid, potassium salt UNII Q42OMW3AT8 - CLAVULANATE POTASSIUM
	Clavulanic acid is a beta-lactam structurally related to penicillins. It inactivates some beta-lactamase enzymes thereby preventing inactivation of amoxicillin.
	Read more about Clavulanic acid

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
B4-2496	Tablet	NEIMETH'S CO AMOXICLAV 625MG TABLET TAB 500 mg; 125 mg 2 X 7	NEIMETH'S CO AMOXICLAV 625MG TABLET NEIMETH AMOXICILLIN TRIHYDRATE BP EQ. TO AMOXICILLIN 500MG, DILUTED POTASSIUM CLAVULANATE BP 125MG POM TABLETS 2 X 7 ANTIBIOTIC NEIMETH INTERNATIONAL PHARMACEUTICALS PLC 1, HENRY CARR STREET, IKEJA LAGOS MEDOPHARM PVT LTD 50, KAYARAMBEDU VILLAGE, GUDUVANCHERY- 603 202, INDIA GMP- SATIS; LR- SATIS; FEES- PAID; NP: NA 03/04/2017 R R R B4-2496	30/01/2020
B4-5809	Powder for injection	Co-Amoxiclav Injection INJ_PWD 1000 mg; 200 mg 1.2 g x 1's (in vial) + 2 x 10 mL SWFI (in ampoules)	Powder for Solution for Injection in vial plus two ampoules of 10 mL sterile water for injection as diluent	28/02/2024
C4-0272	Tablet	FHL Co-Amoxiclav 1 G Tablet TAB 875 mg; 125 mg	Each tablet contains: Amoxicillin Trihydrate BP equiv. to Amoxicillin 875 mg, Diluted Potassium Clavulanate BP equiv. to Clavulanic Acid 125 mg	20/12/2019
C4-0273	Tablet	FHL Co-Amoxiclav 625 mg Tablet TAB 500 mg; 125 mg	Each tablet contains: Amoxicillin Trihydrate BP equiv. to Amoxicillin 500 mg, Diluted Potassium Clavulanate BP equiv. to Clavulanic Acid 125 mg	20/12/2019
C4-1445	Powder for suspension	Co-Amoxiclav Oral Suspension PWD_F_SOL 200 mg/5 mL; 28.5 mg/5 mL	Powder for Oral Suspension	21/12/2020
C4-1446	Tablet	Co-Amoxiclav 1000 mg Tablets TAB 875 mg; 125 mg		21/12/2020
C4-2029	Powder for injection	Co-Amoxiclav Injection INJ_PWD 1000 mg; 200 mg 1.2 g x 1's (in plain glass vial) + 2 x 10 mL SWFI (in ampoules)	Powder for Solution for Injection	22/10/2022

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J01CR02	Amoxicillin and enzyme inhibitor	J Antiinfectives for systemic use → J01 Antibacterials for systemic use → J01C Beta-lactam antibacterials, penicillins → J01CR Combinations of penicillins, incl. beta-lactamase inhibitors
Discover more medicines within J01CR02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	7428-MEE-0822
HK	Department of Health Drug Office	49813, 50392
IE	Health Products Regulatory Authority	13107, 15610, 15672, 17925, 17953, 30109, 90132, 90258
MT	Medicines Authority	AA565/07902, AA565/07903, AA565/07904, AA807/01201, AA965/00801, AA965/00802, MA1220/00201, MA1220/00202, MA1220/00203, MA807/04101
NG	Registered Drug Product Database	B4-2496, B4-5809, C4-027, C4-0272, C4-0273, C4-1445, C4-1446, C4-2029
PL	Rejestru Produktów Leczniczych	100219244, 100219267
ZA	Health Products Regulatory Authority	52/20.1.2/0776, 53/20.1.2/0464, 53/20.1.2/0465